GSK stock: RBC maintains GBp 1,975 target for GSK stock

Published on 10/16/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK reports results October 28, 2026. GSK stock costs EUR 22.08 on October 16, 2026 at 5:06 p.m. CEST, minus 0.23 percent versus the Xetra close.

Research view and upcoming results

RBC maintained its GBp 1,975 target for GSK on October 13, 2026.
GSK is scheduled to report third-quarter results on October 28, 2026.
GSK stock costs EUR 22.08 at Lang & Schwarz on October 16, 2026 at 5:06 p.m. CEST, minus 0.23 percent versus the Xetra close of October 15, 2026.
GSK trades at a P/E ratio of 15.65, with market capitalization of USD 99.6 billion as of October 16, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

RBC maintained its Sector Perform rating and GBp 1,975 target for GSK on October 13, 2026. The target was 11.52 percent above the GBp 1,771 share price cited with the analyst note. GSK stock was trading at EUR 22.08 at Lang & Schwarz on October 16, 2026 at 5:06 p.m. CEST, minus 0.23 percent versus the Xetra close of October 15, 2026 at EUR 22.13.

October 28 results approach

GSK's next scheduled reporting date is October 28, 2026, before the market opens, according to MarketBeat. The page lists a third-quarter earnings estimate of USD 1.32 per share and revenue of USD 11.73 billion, compared with USD 1.48 per share and USD 11.35 billion in the year-earlier quarter.

Price position on October 16

The euro quotation finished the Xetra session 0.23 percent below its dated close. GSK's current Lang & Schwarz bid was EUR 22.06 and its ask was EUR 22.10 at 5:06 p.m. CEST. The company is also listed on the London Stock Exchange under GSK, while its New York listing trades in USD.

RBC's October 13 note described third-quarter expectations as broadly in line with consensus. It forecast revenue of GBP 8.82 billion against a GBP 8.89 billion consensus estimate, while core earnings per share of GBp 50.80 matched expectations, according to Yahoo Finance.

Valuation and scheduled date

GSK's market capitalization was USD 99.6 billion as of October 16, 2026, and its trailing P/E ratio was 15.65. The dividend yield was 4.00 percent on the same date. These figures frame the upcoming results: the October 28 release will test whether the expected revenue profile and earnings outlook remain aligned with the analyst view.

Comparison with peers

GSK: minus 0.23 percent, P/E 15.65, market capitalization USD 99.6 billion

AstraZeneca (London Stock Exchange, GBp): minus 1.72 percent, P/E 24.92, market capitalization GBP 193.6 billion

Pfizer (NYSE, USD): plus 0.65 percent, P/E 39.14, market capitalization USD 168.9 billion

What the next figures may clarify

For investors, the key comparison is between the October 28 revenue figure and the GBP 8.89 billion consensus cited by RBC. The analyst target remains a dated benchmark rather than a forecast from this report.

GSK stock was trading at EUR 22.08 at Lang & Schwarz on October 16, 2026 at 5:06 p.m. CEST, minus 0.23 percent versus the Xetra close of October 15, 2026 at EUR 22.13. The further course of trading is shown by the continuously updated real-time quote of GSK stock.